Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MGAM | O43451 | 1/20 | 0.61 |
| ▸ | SI | P14410 | 1/20 | 0.61 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28149561 | 0.86 | MGAM (0.50) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL12513505 | 0.85 | CA2 (0.59) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL5074737 | 0.83 | GAA (0.56) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL21647241 | 0.82 | GAA (0.45) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL22169089 | 0.81 | GAA (0.54) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL1603754 | 0.80 | CYP1A2 (0.47) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL17720258 | 0.80 | GAA (0.58) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL4467943 | 0.80 | GAA (0.58) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL2003743 | 0.80 | GAA (0.58) | GAAMGAMSIMGAM2ALDH1A1 | |
| Malonic Acid Diethyl Ester SCHEMBL356490 | 0.80 | GAA (0.94) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103965381-B | A kind of titanium tetrachloride initiator system altogether and the method being used for preparing high-activity polyisobutylene thereof | 北京化工大学 | 2016-08-24 | — | — | CN | claimed |
| CN-103965381-A | Titanium tetrachloride co-initiation system, and method for preparing high-reaction-activity polyisobutylene by using it | UNIV BEIJING CHEMICAL | 2014-08-06 | — | — | CN | claimed |
| CN-1176123-C | Initiation system for preparing polyisobutene with reactive activity | 北京化工大学 | 2004-11-17 | — | — | CN | claimed |
| CN-1323841-A | Initiation system for preparing polyisobutene with reactive activity | UNIV BEIJING CHEMICAL ENG (CN) | 2001-11-28 | — | — | CN | claimed |
| US-20240132506-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11845754-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-112996790-B | Compounds, compositions and methods for modulating CDK9 activity | 克洛诺斯生物公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20220002305-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002305-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2022-01-06 | — | — | US | disclosed |
| US-11155560-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2021-10-26 | — | — | US | disclosed |
| US-11155560-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3873911-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| WO-2009068512-A1 | 2 -AMINO-PYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS | PALAU PHARMA, S. A. (ES) | 2009-06-04 | — | — | WO | disclosed |
| US-7217730-B2 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2007-05-15 | — | — | US | disclosed |
| CN-1655778-A | Methods of treating hepatitis C virus infection using pyranoindole derivatives | WYETH CORP (US) | 2005-08-17 | — | — | CN | disclosed |
| EP-1509225-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2005-03-02 | — | — | EP | disclosed |
| CN-1176123-C | Initiation system for preparing polyisobutene with reactive activity | 北京化工大学 | 2004-11-17 | — | — | CN | disclosed |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003099275-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2003-12-04 | — | — | WO | disclosed |
| CN-1323841-A | Initiation system for preparing polyisobutene with reactive activity | UNIV BEIJING CHEMICAL ENG (CN) | 2001-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | HAVCR2, HCCS, ZC3HAV1 | GAA 4301/4885MGAM 4346/4885SI 2467/4885 |
| US-20240132506-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | CDK9, CDK19, CDK7 | GAA 2783/4885MGAM 3920/4885SI 2829/4885 |
| US-11845754-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | CDK9, CDK19, CDK7 | GAA 3387/4885MGAM 4173/4885SI 3486/4885 |
| US-20220002305-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | CDK9, CDK19, CDK7 | GAA 2783/4885MGAM 3920/4885SI 2829/4885 |
| US-11155560-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | CDK9, CDK19, CDK7 | GAA 3387/4885MGAM 4173/4885SI 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.